Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Debt and Interest (Tables)

Debt and Interest (Tables)

9 Months Ended

Sep. 30, 2016

Long-term debt to IDB, NSC and Helocyte consists of the following as of September 30, 2016 and December 31, 2015:

	September 30,		December 31,
($ in thousands)	2016		2015		Interest rate			Maturity
IDB Note	$	14,929	$	14,009		2.25	%	Feb - 2018
NSC Note		7,208		10,000		8.00	%	Mar - 2018
Helocyte Convertible Note, at fair value		3,031				5.00% -8.00	%	Dec - 2017
Opus Credit Facility		5,000				12	%	Sep - 2018
Total notes payable, long-term		30,168		24,009
Less: Discount on notes payable		2,764		835
Total notes payable, long-term, net	$	27,404	$	23,174

Schedule Of Interest Expenses For Debt Arrangements

The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest and amortization of the debt discount and amortization of fees associated with loan transaction costs, amortized over the life of the loan:

	For the Three Months				For the Nine Months
	Ended September 30,				Ended September 30,
($ in thousands)	2016		2015		2016		2015
IDB Note
Interest	$	84	$	82	$	243	$	235
Amortization of fees		-		1		1		3
Total IDB Note		84		83		244		238

NSC Debt
Interest		145		208		456		488
Amortization of fees		135		59		557		140
Total NSC Debt		280		267		1,013		628

Ovamed
Interest		-		-		-		167
Total Ovamed		-		-		-		167

LOC Fees
Interest		3		-		10		-
Total LOC		3		-		10		-

Helocyte Convertible Note
Interest		26		-		26		-
Financing fees		242		-		491		-
Total Helocyte		268		-		517		-

Opus Credit Facility
Interest		26		-		26		-
Amortization of Fees		28		-		28		-
Total Opus		54		-		54		-
Total Interest Expense	$	689	$	350	$	1,838	$	1,033